We also performed control experiments by profiling 43 CpGs from the CpG island of the p15/INK4B (CDKN2B) promoter (located on chromosome 9p21), known to be variably methylated in AML/MDS [20], and of the CpG island of the NY-ESO-1 promoter (located on the X chromosome) known to be very heavily methylated in primary AML/MDS [21]. The gene discussed is CDKN2B; the disease is acute myeloid leukemia.